具有癌特征的肝母细胞瘤代表儿童及年轻成人侵袭性肿瘤的生物学谱系
本研究对具有癌特征的肝母细胞瘤(HBC)进行分子表征,发现其兼具肝母细胞瘤与肝细胞癌的分子特征,与高突变率及复发染色体增益相关,临床结局差,且移植患者结局可能优于单纯化疗加手术。
要点
- HBC包括HCN NOS和HB FPA,具有肝细胞癌的分子特征。
- HBC与高突变率(约3个体细胞突变/Mb)及2q、6p、20p增益相关。
- HBC临床结局差,移植患者可能优于化疗加手术。
核心结论
- HBC的组织学特征与HB和HCC的联合分子特征相关,无论患者年龄如何均与不良结局相关。
- 移植患者比仅接受化疗和手术的患者更可能获得良好结局。
研究设计与样本
- 对临床注释的HCN NOS病例进行首次分子表征,比较其拷贝数变异、突变和基因表达谱与其他儿童肝肿瘤。
主要发现
- HCN NOS和HB FPA的分子谱显示与HCC中先前观察到的共同生物学特征。
- HBC与高突变率(约3个体细胞突变/Mb)相关,并富集关键癌症基因和通路的突变与改变。
- 观察到复发大规模染色体增益,包括2q(80%)、6p(70%)和20p(70%)增益。
- 总体而言,HBC与不良临床结局相关。
临床怎么用
- 作者认为分子检测和早期治疗干预对侵袭性儿童肝细胞肿瘤重要。
- 作者提出结合组织学和分子特征的诊断算法来识别这些癌症。
- 作者分析提示这些癌症可能受益于不同于其他儿童肝癌治疗指南的专门治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the predominant liver cancers in children, though their respective treatment options and associated outcomes differ dramatically. Risk stratification using a combination of clinical, histological, and molecular parameters can improve treatment selection, but it is particularly challenging for tumors with mixed histological features, including those in the recently created hepatocellular neoplasm not otherwise specified (HCN NOS) provisional category. We aimed to perform the first molecular characterization of clinically annotated cases of HCN NOS. METHODS: We tested whether these histological features are associated with genetic alterations, cancer gene dysregulation, and outcomes. Namely, we compared the molecular features of HCN NOS, including copy number alterations, mutations, and gene expression profiles, with those in other pediatric hepatocellular neoplasms, including HBs and HCCs, as well as HBs demonstrating focal atypia or pleomorphism (HB FPAs), and HBs diagnosed in older children (>8). RESULTS: Molecular profiles of HCN NOS and HB FPAs revealed common underlying biological features that were previously observed in HCCs. Consequently, we designated these tumor types collectively as HBs with HCC features (HBCs). These tumors were associated with high mutation rates (∼3 somatic mutations/Mb) and were enriched with mutations and alterations in key cancer genes and pathways. In addition, recurrent large-scale chromosomal gains, including gains of chromosomal arms 2q (80%), 6p (70%), and 20p (70%), were observed. Overall, HBCs were associated with poor clinical outcomes. CONCLUSIONS: Our study indicates that histological features seen in HBCs are associated with combined molecular features of HB and HCC, that HBCs are associated with poor outcomes irrespective of patient age, and that transplanted patients are more likely to have good outcomes than those treated with chemotherapy and surgery alone. These findings highlight the importance of molecular testing and early therapeutic intervention for aggressive childhood hepatocellular neoplasms. LAY SUMMARY: We molecularly characterized a class of histologically aggressive childhood liver cancers and showed that these tumors are clinically aggressive and that their observed histological features are associated with underlying recurrent molecular features. We proposed a diagnostic algorithm to identify these cancers using a combination of histological and molecular features, and our analysis suggested that these cancers may benefit from specialized treatment strategies that may differ from treatment guidelines for other childhood liver cancers.
引用
- Sumazin P, Peters TL, Sarabia SF, et al. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022. PMID: 35577029. doi:10.1016/j.jhep.2022.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。